The goal was to compare static magnetic field (SMF) vasodilator capacity with verapamil (VER) a potent Ca2+ channel blocking agent infusion, aimed to asses SMF potential implementation in conditions with vascular ischemia. Mean femoral artery blood pressure, heart rate and ear lobe skin microcirculatory blood flow measured by microphotoelectric plethysmogram (MPPG) were simultaneously recorded in conscious rabbits after 40-min carotid baroreceptor exposure to 0.35 T SMF (SMF-Car, n = 14) or 0.25 T SMF, generated by Nd-Fe-B magnets, exposed directly to ear microvascular net (SMF-Ves, n = 20), Fig. 1a, and compared with that after 30 min VER i.v. infusion (20 mg kg-1 min-1, n = 20), Fig. 1b. The principal finding is that SMF-Car, SMF-Ves and VER significantly increased microcirculation by: 22.6 ± 11.11%, 17.9 ± 9.58% and 30.5 ± 14.06% (mean ± SEM) resp. and that was no significant difference between all of three treatments (p = 0.986). Microvascular dilation was accompanied by significant decrease of baroreflex sensitivity in VER and its increase in SMF-Car coupled with enhanced vessel sensitivity to nitric oxide dilatory effect. This suggests SMF strong, comparable with VER vasodilator property tailored to address neural and myogenic component of microvascular dysfunction in diabetic foot and nephropathy especially employing both SMFs vasodilation synergy.
J. Gmitrov: None.